Kong Yiu Cheung Acquires 500,000 Shares of NewGenIvf Group (NASDAQ:NIVF) Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung bought 500,000 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were bought at an average price of $1.33 per share, with a total value of $665,000.00. Following the completion of the transaction, the director owned 722,223 shares of the company’s stock, valued at $960,556.59. The trade was a 225.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The stock was bought at an average cost of $1.00 per share, with a total value of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The stock was bought at an average cost of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Trading Down 2.5%

NewGenIvf Group stock opened at $1.18 on Friday. NewGenIvf Group Limited has a fifty-two week low of $1.11 and a fifty-two week high of $1,539.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. The firm’s fifty day moving average price is $2.79 and its 200-day moving average price is $10.97.

Analyst Ratings Changes

NIVF has been the subject of a number of research reports. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, NewGenIvf Group has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.